151 related articles for article (PubMed ID: 36001383)
1. Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.
Wimberger P; Gerber MJ; Pfisterer J; Erdmann K; Füssel S; Link T; du Bois A; Kommoss S; Heitz F; Sehouli J; Kimmig R; de Gregorio N; Schmalfeldt B; Park-Simon TW; Baumann K; Hilpert F; Grube M; Schröder W; Burges A; Belau A; Hanker L; Kuhlmann JD
Clin Cancer Res; 2022 Nov; 28(21):4660-4668. PubMed ID: 36001383
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
3. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity.
Ngo DT; Farb MG; Kikuchi R; Karki S; Tiwari S; Bigornia SJ; Bates DO; LaValley MP; Hamburg NM; Vita JA; Hess DT; Walsh K; Gokce N
Circulation; 2014 Sep; 130(13):1072-80. PubMed ID: 25116954
[TBL] [Abstract][Full Text] [Related]
5. The role of VEGF-A165b in trophoblast survival.
Bills VL; Hamdollah-Zadeh M; Soothill PW; Harper SJ; Bates DO
BMC Pregnancy Childbirth; 2014 Aug; 14():278. PubMed ID: 25128406
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
7. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.
Beazley-Long N; Hua J; Jehle T; Hulse RP; Dersch R; Lehrling C; Bevan H; Qiu Y; Lagrèze WA; Wynick D; Churchill AJ; Kehoe P; Harper SJ; Bates DO; Donaldson LF
Am J Pathol; 2013 Sep; 183(3):918-29. PubMed ID: 23838428
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
9. VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients.
Ding Y; Oliveira-Ferrer L; Vettorazzi E; Legler K; Milde-Langosch K; Woelber L; Jaeger A; Prieske K; Mueller V; Schmalfeldt B; Kuerti S
PLoS One; 2022; 17(6):e0269680. PubMed ID: 35687576
[TBL] [Abstract][Full Text] [Related]
10. WNT5A regulates adipose tissue angiogenesis via antiangiogenic VEGF-A
Karki S; Ngo DTM; Farb MG; Park SY; Saggese SM; Hamburg NM; Carmine B; Hess DT; Walsh K; Gokce N
Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H200-H206. PubMed ID: 28411232
[TBL] [Abstract][Full Text] [Related]
11. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
Hamdollah Zadeh MA; Amin EM; Hoareau-Aveilla C; Domingo E; Symonds KE; Ye X; Heesom KJ; Salmon A; D'Silva O; Betteridge KB; Williams AC; Kerr DJ; Salmon AH; Oltean S; Midgley RS; Ladomery MR; Harper SJ; Varey AH; Bates DO
Mol Oncol; 2015 Jan; 9(1):167-78. PubMed ID: 25224594
[TBL] [Abstract][Full Text] [Related]
13. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
15. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
Varey AH; Rennel ES; Qiu Y; Bevan HS; Perrin RM; Raffy S; Dixon AR; Paraskeva C; Zaccheo O; Hassan AB; Harper SJ; Bates DO
Br J Cancer; 2008 Apr; 98(8):1366-79. PubMed ID: 18349829
[TBL] [Abstract][Full Text] [Related]
16. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Chambers SK; Clouser MC; Baker AF; Roe DJ; Cui H; Brewer MA; Hatch KD; Gordon MS; Janicek MF; Isaacs JD; Gordon AN; Nagle RB; Wright HM; Cohen JL; Alberts DS
Clin Cancer Res; 2010 Nov; 16(21):5320-8. PubMed ID: 21041183
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Han ES; Burger RA; Darcy KM; Sill MW; Randall LM; Chase D; Parmakhtiar B; Monk BJ; Greer BE; Connelly P; Degeest K; Fruehauf JP
Gynecol Oncol; 2010 Dec; 119(3):484-90. PubMed ID: 20870280
[TBL] [Abstract][Full Text] [Related]
19. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
Bates DO; Catalano PJ; Symonds KE; Varey AH; Ramani P; O'Dwyer PJ; Giantonio BJ; Meropol NJ; Benson AB; Harper SJ
Clin Cancer Res; 2012 Nov; 18(22):6384-91. PubMed ID: 23104894
[TBL] [Abstract][Full Text] [Related]
20. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
